These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 37138160)

  • 41. Feasibility of repeat and bilateral submandibular gland needle biopsies in Parkinson's disease.
    Adler CH; Serrano GE; Zhang N; Hinni ML; Lott DG; Mehta SH; Sue LI; Intorcia A; Beach TG
    Parkinsonism Relat Disord; 2019 Nov; 68():69-72. PubMed ID: 31621624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ⍺-Synuclein Structural Diversity and the Cellular Environment in ⍺-Synuclein Transmission Models and Humans.
    Peelaerts W; Baekelandt V
    Neurotherapeutics; 2023 Jan; 20(1):67-82. PubMed ID: 37052776
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo.
    Dominguez-Meijide A; Parrales V; Vasili E; González-Lizárraga F; König A; Lázaro DF; Lannuzel A; Haik S; Del Bel E; Chehín R; Raisman-Vozari R; Michel PP; Bizat N; Outeiro TF
    Neurobiol Dis; 2021 Apr; 151():105256. PubMed ID: 33429042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.
    Li X; Koudstaal W; Fletcher L; Costa M; van Winsen M; Siregar B; Inganäs H; Kim J; Keogh E; Macedo J; Holland T; Perry S; Bard F; Hoozemans JJ; Goudsmit J; Apetri A; Pascual G
    Acta Neuropathol; 2019 May; 137(5):825-836. PubMed ID: 30805666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease.
    Kang UJ; Boehme AK; Fairfoul G; Shahnawaz M; Ma TC; Hutten SJ; Green A; Soto C
    Mov Disord; 2019 Apr; 34(4):536-544. PubMed ID: 30840785
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology.
    Esteves AR; Palma AM; Gomes R; Santos D; Silva DF; Cardoso SM
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2008-2023. PubMed ID: 30572013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC.
    Groveman BR; Orrù CD; Hughson AG; Raymond LD; Zanusso G; Ghetti B; Campbell KJ; Safar J; Galasko D; Caughey B
    Acta Neuropathol Commun; 2018 Feb; 6(1):7. PubMed ID: 29422107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders.
    Bräuer S; Rossi M; Sajapin J; Henle T; Gasser T; Parchi P; Brockmann K; Falkenburger BH
    Acta Neuropathol Commun; 2023 Oct; 11(1):162. PubMed ID: 37814347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies.
    Rossi M; Candelise N; Baiardi S; Capellari S; Giannini G; Orrù CD; Antelmi E; Mammana A; Hughson AG; Calandra-Buonaura G; Ladogana A; Plazzi G; Cortelli P; Caughey B; Parchi P
    Acta Neuropathol; 2020 Jul; 140(1):49-62. PubMed ID: 32342188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays.
    Candelise N; Schmitz M; Thüne K; Cramm M; Rabano A; Zafar S; Stoops E; Vanderstichele H; Villar-Pique A; Llorens F; Zerr I
    Transl Neurodegener; 2020; 9():5. PubMed ID: 31988747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
    Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
    Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
    Sengupta U; Kayed R
    Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies.
    Moors TE; Mona D; Luehe S; Duran-Pacheco G; Spycher L; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Dernick G; van de Berg WDJ; Britschgi M
    Acta Neuropathol Commun; 2022 Jun; 10(1):82. PubMed ID: 35659116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Seeding variability of different alpha synuclein strains in synucleinopathies.
    Candelise N; Schmitz M; Llorens F; Villar-Piqué A; Cramm M; Thom T; da Silva Correia SM; da Cunha JEG; Möbius W; Outeiro TF; Álvarez VG; Banchelli M; D'Andrea C; de Angelis M; Zafar S; Rabano A; Matteini P; Zerr I
    Ann Neurol; 2019 May; 85(5):691-703. PubMed ID: 30805957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultrasensitive RT-QuIC Seed Amplification Assays for Disease-Associated Tau, α-Synuclein, and Prion Aggregates.
    Saijo E; Groveman BR; Kraus A; Metrick M; Orrù CD; Hughson AG; Caughey B
    Methods Mol Biol; 2019; 1873():19-37. PubMed ID: 30341601
    [TBL] [Abstract][Full Text] [Related]  

  • 58. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
    Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
    J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.
    Landeck N; Hall H; Ardah MT; Majbour NK; El-Agnaf OM; Halliday G; Kirik D
    Mol Neurodegener; 2016 Aug; 11(1):61. PubMed ID: 27549140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.